ArticleInternational journal of emergency medicine2025
Comparison of the effects of inhalant furosemide, oxygen therapy, and placebo in patients with acute dyspnea referred to emergency departments by EMS in various hospitals in Tehran.
Article in International journal of emergency medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute dyspnea is a common presentation in emergency departments (EDs), which is one of the main complaints of the patients. There is an urgent need for an effective treatment plan for dyspnea. This study aims to compare the efficacy of inhalant furosemide, oxygen therapy, and placebo in patients with acute dyspnea referred to EDs in Tehran by Emergency Medical Services (EMS).
methodsThis randomized clinical trial included patients aged 18 to 75 who experienced acute dyspnea and were delivered to the ED by EMS during 2021 and 2022. Participants were randomly assigned to one of three groups: inhalant furosemide, oxygen therapy, or placebo (distilled water) which every group received the medication before entering EDs in a prehospital setting.
resultsThe mean age of patients was 52.63 ± 20.48 years including 124 women (47.7%) and 136 men (52.3%). Our finding indicates that dyspnea intensity, heart rate, blood pressure, and oxygen saturation showed no significant differences among the groups (p-value). However, these parameters significantly improved in both the treatment and placebo groups (p-value). The mean degree of dyspnea in the furosemide group was lower than that in the other two groups, although the difference was not statistically significant. Hospitalization duration was significantly shorter in the furosemide group compared to the oxygen therapy and placebo groups. Conversely, ICU admission duration was significantly shorter in the oxygen therapy group than in the other two groups. Patient satisfaction levels did not differ significantly across groups.
conclusionThe main effect of inhalant Furosemide in this study was reducing the patient's length of hospitalization. It seems that Furosemide can have positive effects and can be used as a cure according to its low side effects, also this drug isn't expensive and its mechanism of action, side effects, and pharmacokinetics have been shown and understood.
trial registrationThis study was registered with the IUMS Ethics Committee, receiving the ethical code (IR.IUMS.REC.1399.632), it was also listed in the Iranian Registry of Clinical Trails (IRCT20151003024317N12) on November the 10th, 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.